NCT01753804
Duchenne Muscular Dystrophy
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
To characterize the natural history and progression of Duchenne Muscular Dystrophy (DMD) to help inform the design of future studies, to capture biomarkers of safety and disease progression and to provide comparative data for the development of rare exons for which formal controlled trials are not feasible.
Male
3 Years to 18 Years
No
Observational study
Observational
269
2012-09-01
2017-12-08
Sacramento, California, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Buenos Aires, , Argentina
Gent, , Belgium
Leuven, , Belgium
Sao Paulo, , Brazil
Toulouse, , France
Essen, , Germany
Freiburg, , Germany
Messina, , Italy
Rome, , Italy
Leiden, , Netherlands
Nijmegen, , Netherlands
Goteborg, , Sweden
Ankara, , Turkey
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields